---
trial_id: 1894
discovery_date: 2022-10-01 16:58:48.404026
date: 2022-10-01 16:58:48.404026
title: "Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis"
summary: |
  <p>EudraCT Number: 2016-004719-10<br />Sponsor Protocol Number: AC-058B303<br />Sponsor Name: Actelion Pharmaceuticals Ltd.<br />Start Date: 2017-10-02<br />Medical condition: relapsing multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/SE">SE</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LV">LV</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HR">HR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/FI">FI</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/RO">RO</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004719-10'
published_date: NaT
trial_source: 
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2016-004719-10<br />Sponsor Protocol Number: AC-058B303<br />Sponsor Name: Actelion Pharmaceuticals Ltd.<br />Start Date: 2017-10-02<br />Medical condition: relapsing multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/SE">SE</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LV">LV</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HR">HR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/FI">FI</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/RO">RO</a> (Ongoing)</p>